EFMC-ISMC 2016

ONLINE REGISTRATION is still OPEN!

Media Partner

Discover Manchester!

***
Join our Group on LinkedIn for regular updates!
***

Conferences > Archives > EFMC-ISMC 2016

Confirmed Speakers


Award & Prize Lectures

Prof. François DIEDERICH
Prof. François DIEDERICH
ETH ZURICH, Zürich, Switzerland

Read more

NAUTA AWARD FOR PHARMACOCHEMISTRY
Molecular Recognition Studies with Chemical and Biological Systems: A Multi-Dimensional Approach to Support Structure-Based Drug Design

Prof. Paul J.  HERGENROTHER
Prof. Paul J. HERGENROTHER
UNIVERSITY OF ILLINOIS, Urbana, United States
Read more

UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
Traversing the Valley of Death in Anticancer Drug Discovery

Dr Michael SOFIA
Dr Michael SOFIA
ARBUTUS BIOPHARMA, Doylestown, PA, United States
Read more

IUPAC-RICHTER PRIZE
The Discovery of Sofosbuvir: A Breakthrough Curative Therapy for Hepatitis C

Prof. Jan STEYAERT
Prof. Jan STEYAERT
VUB, Brussels, Belgium
Read more

PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Nanobody-Enabled HTS for the Discovery of GPCR Agonists

Plenary Lectures

Prof. Klaus BOCK
Prof. Klaus BOCK
UNIVERSITY OF COPENHAGEN , Copenhagen, Denmark
Read more

The European Research Council (ERC) and its Support for Medicinal Chemistry

Prof. Jeffrey BODE
Prof. Jeffrey BODE
ETH ZÜRICH, Zürich, Switzerland

Read more

Cross-Coupling Approaches to Saturated N-Heterocycles

Sir Simon CAMPBELL
Sir Simon CAMPBELL
SCIENTIFIC CONSULTANT, Poole, United Kingdom
Read more

Science, Art and Drug Discovery, a Personal Perspective

Dr Derek LOWE
Dr Derek LOWE
VERTEX PHARMACEUTICALS, Cambridge, United States
Read more

Robotics, Artificial Intelligence, and Medicinal Chemistry: A Look Into the Future

Prof. Dario NERI
Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
Read more

DNA-Encoded Chemical Libraries

Prof. Tobias RITTER
Prof. Tobias RITTER
MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany
Read more

Late-Stage Fluorination

Dr Anthony WOOD
Dr Anthony WOOD
PFIZER, Waltham, United States
Read more

Heterocycles and Medicinal Chemistry: The Importance of Innovative Synthesis 

Invited Speakers


Peptide Drugs to Target GPCR - State of the Art and Innovative Applications

Dr Carmen ALMANSA
Dr Carmen ALMANSA
ESTEVE, Barcelone, Spain
Read more

Challenges in the Discovery of Sigma-1 Receptor Antagonists for the Treatment of Pain

Prof. Jonathan BAELL
Prof. Jonathan BAELL
MONASH UNIVERSITY, Parkville, Australia
Read more

Histone Acetyltransferase Inhibitors, from Screening to Optimization - a Tricky Track

Dr Makonen  BELEMA
Dr Makonen BELEMA
BRISTOL-MYERS SQUIBB, Wallingford, United States
Read more

Direct and Synergistic Inhibition of The HCV NS5A Protein

Dr Goncalo BERNARDES
Dr Goncalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Lisbon, Portugal
Read more

RSC Prize Lecture:
Chemical Pharmacology of Protein Conjugates and Natural Products (2016 Chem Soc Rev Emerging Investigator Lectureship)


Dr Paul BESWICK
UNIVERSITY OF SUSSEX, Brighton, United Kingdom
Read more

The Painful Reality of Drug Discovery and Development

Prof. Maria Laura BOLOGNESI
Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Read more

Tackling Neurodegenerative Diseases Through Multi-Target and Theranostic Small Molecules

Prof. Martin D. BURKE
Prof. Martin D. BURKE
UNIVERSITY OF ILLINOIS, Urbana, United States
Read more

Towards a More Generalized and Automated Approach for Small Molecule Synthesis

Dr Michael BÖTTGER
Dr Michael BÖTTGER
BAYER PHARMA, Wuppertal, Germany
Read more

Regorafenib Eye Drops for Wet AMD – Challenges in Translatability of Preclinical Data Into Clinical Efficacy

Prof. Giulia CARON
Prof. Giulia CARON
UNIVERSITY OF TORINO, Torino, Italy
Read more

The Need of Implementing Intramolecular Hydrogen Bonding (IMHB) Considerations in Drug Discovery and How to do it

Prof. Alessio CIULLI
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Read more

RSC Prize Lecture:
Advanced Chemical Genetics for Epigenetics: Bump and Hole and PROTACs (2016 MedChemComm Emerging Investigator Lectureship)

Dr Miles CONGREVE
Dr Miles CONGREVE
HEPTARES, Welwyn Garden City, United Kingdom
Read more

Identification of Allosteric Inhibitors of GPCRs Using SBDD

Prof. Benoit DEPREZ
Prof. Benoit DEPREZ
UNIVERSITY OF LILLE 2, Lille, France
Read more

Pharmacological Reversion of Antibiotic Resistance in Mycobacterium Tuberculosis : Design of SMART Trojan Molecules to Reprogram The Bacteria

Dr Eric DESARBRE
Dr Eric DESARBRE
BASILEA PHARMACEUTICA, Basel, Switzerland
Read more

New Antibacterial Agents in the Pipeline

Prof. Alexander DÖMLING
Prof. Alexander DÖMLING
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
Read more

Expanding the Macrocycle Chemical Space

Prof. Gerhard ECKER
Prof. Gerhard ECKER
UNIVERSITY OF VIENNA, Vienna, Austria
Read more

Exploiting Linked Open Data - Transporter Profiling and Beyond

Dr Steven ELMORE
Dr Steven ELMORE
ABBVIE, North Chicago, United States
Read more

Releasing the Brake on Apoptosis. Discovery of Bcl-2 Family Protein Inhibitors

Prof. Patrick EYERS
Prof. Patrick EYERS
UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom
Read more

New Pseudokinase Drug Targets in the Human Kinome

Dr Daniel FLYNN
Dr Daniel FLYNN
DECIPHERA PHARMACEUTICALS, Lawrence, United States
Read more

Switch Control Inhibitors: an Advance in Type II Kinase Inhibition

Dr Fabrizio GIORDANETTO
Dr Fabrizio GIORDANETTO
D.E. SHAW RESEARCH LLC, New York, United States
Read more

Intramolecular Hydrogen Bond Expectations in Medicinal Chemistry

Dr Cristiano GUIMARAES
Dr Cristiano GUIMARAES
ACHÉ PHARMACEUTICAL, Brazil
Read more

Research, Development & Innovation at Aché Laboratórios Farmacêuticos

Dr Wolfgang HAAP
Dr Wolfgang HAAP
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Discovery and Development of the Highly Potent, Highly Selective Cathepsin S Inhibitor RG7625 for the Treatment of Autoimmune Diseases

Prof. Christian HEINIS
Prof. Christian HEINIS
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland
Read more

Phage-Encoded Combinatorial Chemical Libraries Based on Bicyclic Peptides


Dr David HEPWORTH
PFIZER MEDICINES DESIGN, Cambridge, United States
Read more

The Design and Evaluation of URAT1 Inhibitors for the Treatment of Hyperuricemia and Gout

Dr Jörg HOLENZ
Dr Jörg HOLENZ
ASTRAZENECA NEUROSCIENCE, Collegeville, United States
Read more

Discovery of AZD3241 is a Potent and Selective Myeloperoxidase Inhibitor for the Treatment of Neurodegenerative Disorders

Dr Philip HOWARD
Dr Philip HOWARD
SPIROGEN LTD, London, United Kingdom
Read more

The Development of Pyrrolobenzodiazepine in Antibody Drug Conjugates

Dr Robert T. JACOBS
Dr Robert T. JACOBS
ANACOR PHARMACEUTICALS, Palo Alto, California, United States
Read more

Utilization of Novel Benzoxaboroles as Drug Candidates to Treat Neglected Tropical Diseases

Dr Johanna JANSEN
Dr Johanna JANSEN
NOVARTIS, Emeryville, United States
Read more

Inhibition of Prenylated KRAS: Tools to Discover and Characterize RAS Ligands

Dr Neil W. JOHNSON
Dr Neil W. JOHNSON
GLAXOSMITHKLINE, Collegeville, United States
Read more

The Identification of GSK2879552, a Mechanism Based Irreversible Inhibitor of the Histone Lysine Demethylase LSD1

Dr Eric KARRAN
Dr Eric KARRAN
FOUNDATIONAL NEUROSCIENCE CENTER, ABBVIE, Cambridge, United States
Read more

Possibilities and Pitfalls: Disease Modifying Drugs for Alzheimer's Disease

Prof. Douglas KELL
Prof. Douglas KELL
UNIVERSITY OF MANCHESTER, Manchester, United Kingdom
Read more

The Cellular Uptake of Pharmaceutical Drugs is Transporter-Mediated - A Problem not of Biophysics but of Systems Biology

Dr Horst KESSLER
Dr Horst KESSLER
TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany
Read more

Peptides and Peptidomimetics: Overcoming Problems of Activity, Selectivity and Bioavailability of Integrin Ligands

Prof. Ross KING
Prof. Ross KING
UNIVERSITY OF MANCHESTER, Manchester, United Kingdom
Read more

Robot Scientists, the Replication Crisis, and Cancer

Prof. Stefan KNAPP
Prof. Stefan KNAPP
GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany
Read more

Validating New Epigenetic Targets by Selective Protein Interaction Inhibitors of Bromodomains

Dr Joe KOZLOWSKI
Dr Joe KOZLOWSKI
MERCK, SHARP & DOHME, Rahway, United States
Read more

Discovery of the HCV NS5A Inhibitor MK-8408 (RUZASVIR)

Dr Bernd KUHN
Dr Bernd KUHN
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Intramolecular Hydrogen Bonding as a Design Element in Medicinal Chemistry

Dr Jin LI
Dr Jin LI
HITGEN LTD , Chengdu, Sichuan, China
Read more

DNA-Encoded Chemical Library for Protein-Protein Interactions

Dr John LIDDLE
Dr John LIDDLE
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

First Time Disclosure of a Development Candidate to Treat Severe Acute Pancreatitis through a Drug Discovery Partnership Between GSK and the University of Edinburgh

Prof. Philip S. LOW
Prof. Philip S. LOW
PURDUE UNIVERSITY, West Lafayette, United States
Read more

Ligand-Targeted Therapeutic and Imaging Agents for Multiple Human Diseases

Prof. Antonio MACCHIARULO
Prof. Antonio MACCHIARULO
UNIVERSITY OF PERUGIA, Perugia, Italy
Read more

Targeting the Janus-Faced Nature of IDO1 in Immuno-Oncology

Dr Gaëtan MISLIN
Dr Gaëtan MISLIN
UNIVERSITY OF STRASBOURG, Illkirch-Graffenstaden, France
Read more

Enterobactin-Dependent Iron Uptake Pathway as a Gate for Antibiotic Trojan Horse Strategies Against Pseudomonas Aeruginosa

Dr Muneto MOGI
Dr Muneto MOGI
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
Read more

The Back of The Eye: Treatment Challenges and Opportunities

Prof. Carlos MONTANARI
Prof. Carlos MONTANARI
UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil
Read more

Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors

Prof. Christa MÜLLER
Prof. Christa MÜLLER
UNIVERSITY OF BONN, Bonn, Germany
Read more

Medicinal Chemistry of Purinergic Signalling: Targets and Drugs for the Immunotherapy of Cancer

Prof. Cristina NEVADO
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
Read more

Potent and Highly Selective Bromodomain Ligands… a Platform for Reaction Discovery

Dr Ronan O'HAGAN
Dr Ronan O'HAGAN
MERCK, SHARP & DOHME, Boston, United States
Read more

Small Molecule Approaches to Immune-Modulation in Cancer

Prof. Krzysztof  PALCZEWSKI
Prof. Krzysztof PALCZEWSKI
CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States
Read more

Molecular Pharmacodynamics of Visual Cycle Modulators in Protection Against Retinal Degeneration

Prof. Zhengying PAN
Prof. Zhengying PAN
PEKING UNIVERSITY, Shenzhen, China
Read more

Targeted Covalent Inhibitors of Bruton's Tyrosine Kinases - Design, Evaluation and Follow-up

Dr Janeta POPOVICI-MULLER
Dr Janeta POPOVICI-MULLER
AGIOS PHARMACEUTICALS, United States
Read more

Discovery of AG-120 – A First-in-class Inhibitor of IDH1 Mutant Enzymes for the Treatment of Cancers Harboring IDH1 Mutations

Dr Scott PRIESTLEY
Dr Scott PRIESTLEY
BRISTOL-MYERS SQUIBB, Hopewell, United States
Read more

Discovery of a First-in-Class PAR4 Antagonist as a Novel Antithrombotic

Dr Marc ROBILLARD
Dr Marc ROBILLARD
TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands
Read more

Antibody Imaging and Therapy Using in Vivo Click and Click-to-Release Strategies

Dr Carsten SCHMECK
Dr Carsten SCHMECK
BAYER, Wuppertal, Germany
Read more

Discovery of Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure

Prof. Gisbert SCHNEIDER
Prof. Gisbert SCHNEIDER
ETH ZÜRICH, Zürich, Switzerland
Read more

Big Dada in Medicinal Chemistry?

Prof. Christopher J. SCHOFIELD
Prof. Christopher J. SCHOFIELD
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Mechanistic and Inhibition Studies on Metallo-Beta-Lactamases

Prof. Giulio SUPERTI-FURGA
Prof. Giulio SUPERTI-FURGA
RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria
Read more

Solute Carriers, Metabolism and Drug Response: a Magic Triangle

Dr Masahiko TERAKADO
Dr Masahiko TERAKADO
ONO PHARMACEUTICAL, Osaka, Japan
Read more

Discovery of Novel LPA1 Antagonist: Design and SAR Studies

Prof. Peter TIMMERMAN
Prof. Peter TIMMERMAN
PEPSCAN THERAPEUTICS, Lelystad, The Netherlands
Read more

Discovery & Optimzation of Clips-Constrained Bicyclic Peptides (2clips) Using Pepscan Peptide Arrays

Prof. Mariola TORTOSA
Prof. Mariola TORTOSA
AUTONOMOUS UNIVERSITY OF MADRID, Madrid, Spain
Read more

Nucleophilic Boron for the Preparation of Highly Functionalized Small Rings

Prof. Trond ULVEN
Prof. Trond ULVEN
UNIVERSITY OF SOUTHERN DENMARK, København Ø, Denmark
Read more

Targeting Long-Chain Fatty Acid Receptors FFA1 and FFA4 for Treatment of Metabolic Diseases

Dr Herman VAN VLIJMEN
Dr Herman VAN VLIJMEN
JANSSEN, Beerse, Belgium
Read more

Broad Multiparametric Profiling of Kinase Inhibitors

Dr Thomas VON GELDERN
Dr Thomas VON GELDERN
ABBVIE, Chicago, United States
Read more

The Discovery and Development of Novel Macrofilaricidal Agents for the Treatment of Onchocerciasis and Lymphatic Filariasis

Prof. Herbert WALDMANN
Prof. Herbert WALDMANN
MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany
Read more

Chemical Biological Modulation of KRas-Signaling

Dr.  Jon  WINTER-HOLT
Dr. Jon WINTER-HOLT
ASTRAZENECA, Macclesfield, United Kingdom
Read more

Small Molecule Binding Sites on the RAS: SOS Complex Can Be Exploited for Inhibition of RAS Activation

Prof. Alfred WITTINGHOFER
Prof. Alfred WITTINGHOFER
MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany
Read more

Studying Ciliary Trafficking and How it Leads to RAS Drug Candidates

Dr Gail WRIGLEY
Dr Gail WRIGLEY
ASTRAZENECA, Macclesfield, United Kingdom
Read more

Advances in the Development of Covalent EGFR Inhibitors: from Early Hits to Osimertinib

Dr Xiaomin ZHANG
Dr Xiaomin ZHANG
GLAXOSMITHKLINE, Shanghai, China
Read more

Discovery of Brain-Penetrable LpPLA2 Inhibitor for Alzheimer’s Disease

Prof. Huchen ZHOU
Prof. Huchen ZHOU
SHANGHAI JIAO TONG UNIVERSITY, Shanghai, China
Read more

Chemical Biology Efforts in Cancer Drug Discovery

Oral Communication

Dr Neil G BERRY
Dr Neil G BERRY
UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom
Read more

Anti-Wolbachia (A·WOL) Drug Discovery: Novel Hit Finding Via Ligand Based Virtual Screening Combined With HTS

Prof. Frank BÖCKLER
Prof. Frank BÖCKLER
EBERHARD-KARLS UNIVERSITY TUEBINGEN, Tübingen, Germany
Read more

EFMC Prize for a Young Medicinal Chemist in Academia
Sigma Hole Bonding in Kinase Drug Discovery

Prof. Stuart CONWAY
Prof. Stuart CONWAY
UNIVERSITY OF OXFORD, Oxford, United Kingdom

Intramolecular Hydrogen Bonds in the Design of CREBBP Bromodomain Ligands

Dr Stefano CROSIGNANI
Dr Stefano CROSIGNANI
ITEOS THERAPEUTICS SA, Gosselies, Belgium

Discovery of PF-06840003, a Novel IDO1 Inhibitor for Cancer Immunotherapy

Dr Chris DE GRAAF
Dr Chris DE GRAAF
VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands
Read more

Mining Structural Protein-Ligand Interactions to Navigate Medicinal Chemistry Space

Dr Daniela DIGLES
Dr Daniela DIGLES
UNIVERSITY OF VIENNA, Vienna, Austria
Read more

Drug Targets in the Solute Carrier Classification (SLC)

Mr Luiz Antonio DUTRA
Mr Luiz Antonio DUTRA
STATE UNIVERSITY OF SAO PAULO - UNESP, Araraquara, Brazil
Read more

Antiplatelet and Antithrombotic Activity of 1,2,5-Oxadiazole-2-N-Oxide Derivatives

Dr Mark FRALEY
Dr Mark FRALEY
MERCK, SHARP & DOHME, West Point, United States

Discovery of Ubrogepant (MK-1602): a Potent, Selective and Orally Bioavailable CGRP Receptor Antagonist for the Acute Treatment of Migraine

Dr Marcus GASTREICH
Dr Marcus GASTREICH
BIOSOLVEIT, St. Augustin, Germany
Read more

The evoSpace - A Synthesis-Driven Environment that Finds Accessible, Well-Behaved Compounds by Design

Prof. Antimo GIOIELLO
Prof. Antimo GIOIELLO
UNIVERSITY OF PERUGIA, Perugia, Italy
Read more

Atypical Bile Acids as Chemical Probes for Diagnosis and Therapy Monitoring of Progressive Cholestatic Liver Disease in HSD3B7 Patients

Mr Xavier GÓMEZ-SANTACANA
Mr Xavier GÓMEZ-SANTACANA
VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands
Read more

Photoisomerisable Allosteric Modulators Allow a Fine Control of mGlu Receptors with Light in Vivo (EFMC-YMCS Presentation Prize)

Dr Mark HEALY
Dr Mark HEALY
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
Read more

Optimising Membrane Interactions to Achieve Duration of Action for Inhaled Drug Candidates

Ms Shalinee JHA
Ms Shalinee JHA
GRAZ UNIVERSITY OF TECHNOLOGY, Graz, Austria
Read more

Towards Low-Risk Painkillers: Human Dipeptidyl Peptidase III (hDPPIII) as a Novel Target for Therapeutic Pain Intervention

Dr Allan JORDAN
Dr Allan JORDAN
CANCER RESEARCH UK MANCHESTER INSTITUTE, Manchester, United Kingdom
Read more

Delivering First-in-Class In Vitro Chemical Probes Against Poly (ADP Ribose) Glycohydrolase (PARG)

Dr Nir LONDON
Dr Nir LONDON
THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Read more

Rapid Discovery of Potent and Selective Covalent Inhibitors via Covalent Docking

Dr Claudio MAPELLI
Dr Claudio MAPELLI
BRISTOL-MYERS SQUIBB, United States
Read more

Attempts at Oral Delivery of a Series of Short Unnatural Peptides: Still Like Pushing a Camel Through the Eye of a Needle?

Prof. Ana MARTINEZ
Prof. Ana MARTINEZ
CSIC, Madrid, Spain
Read more

Systemic Administration of an Allosteric GSK-3 Inhibitor Delays Photoreceptor Cell Death and Preserves Visual Function in a Retinitis Pigmentosa Mouse Model

Ms Leticia MONJAS GOMEZ
Ms Leticia MONJAS GOMEZ
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
Read more

Exploring Hit-Identification Strategies for Energy-Coupling Factor Transporters, a Novel Target for the Development of Antibiotics

Mrs Michaela MÜLLER
Mrs Michaela MÜLLER
UNIVERSITÄT ZU LÜBECK, Lübeck, Germany
Read more

Classification of Adamts Binding Sites: the First Step Toward Selective ADAMTS7 Inhibitors

Dr Philippe NANTERMET
Dr Philippe NANTERMET
MERCK & CO. INC (MSD), West Point, United States
Read more

Functionally Irreversible Non-Covalent Inhibitors of FAAH: a Safer Approach?

Dr David NORTON
Dr David NORTON
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

From Fragment to in vivo Activity for a Challenging PPI Target: the Discovery of Potent Inhibitors of the KEAP1-NRF2 Interaction

Dr Alleyn T. PLOWRIGHT
Dr Alleyn T. PLOWRIGHT
ASTRAZENECA, Frankfurt-Am-Main, Germany
Read more

Phenotypic Screening for the Discovery of Novel Molecules for Therapeutic Heart Regeneration

Dr Jean QUANCARD
Dr Jean QUANCARD
NOVARTIS, Basel, Switzerland
Read more

EFMC Prize for a Young Medicinal Chemist in Industry
Inhibition of the COP9 Signalosome as a Novel Approach to Treat Cancer”

Dr Neil RANSON
Dr Neil RANSON
UNIVERSITY OF LEEDS, Leeds, United Kingdom
Read more

How can Advances in Cryo-Electron Microscopy Revolutionize Medicinal Chemistry?

Dr Orr RAVITZ
Dr Orr RAVITZ
WILEY, Chichester, United Kingdom
Read more

Identifying Synthetic Opportunities Using Chemplanner - How Computers Assist Chemists in Covering a Greater Synthetic Space

Prof. Christophe ROCHAIS
Prof. Christophe ROCHAIS
UNIVERSITY OF CAEN, Caen, France
Read more

Modulation of RS67,333: from a 5-HT4R Partial Agonist to the Identification of Several Promising Multi-Target Directed Ligands for Alzheimer's Disease

Mr Eduardo RUIVO
Mr Eduardo RUIVO
UNIVERSITY OF ANTWERP, Antwerp, Belgium
Read more

Novel Antibody-Tetrazine Conjugate for Breast Cancer Imaging

Dr Volker K. SCHULZE
Dr Volker K. SCHULZE
BAYER PHARMA AG, Berlin, Germany
Read more

Driving Tumors into Mitotic Catastrophe - Lead Generation of MPS1 Inhibitors Leading to Two Clinical Candidates BAY 1161909 and BAY 1217389

Mrs Gisele SILVESTRE DA SILVA
Mrs Gisele SILVESTRE DA SILVA
UNICAMP, São Paulo, Brazil
Read more

Effects of Novel Acylhydrazones Derived From 4-Quinolone on the Acetylcholinesterase Activity and Aβ42 Peptide Fibrils Formation

Dr Graham SMITH
Dr Graham SMITH
MERCK, SHARP & DOHME, Boston, United States
Read more

Non Coding RNA as a Small Molecule Druggable Target

Dr Nicolas SOLDERMANN
Dr Nicolas SOLDERMANN
NOVARTIS, Basel, Switzerland

First Disclosure of CDZ173 - Discovery of a New Generation of Potent and Selective PI3K Delta Inhibitors for Autoimmune and Inflammatory Diseases

Dr Michael THOMAS
Dr Michael THOMAS
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Read more

The Development of DDD853651; a Potential Candidate for the Treatment of Visceral Leishmaniasis

Dr Tihomir TOMASIC
Dr Tihomir TOMASIC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
Read more

Interaction of 4,5,6,7-Tetrahydrobenzo[1,2-D]Thiazoles with the Cellular Chaperone HSP90 as a Potential Pathway to Inhibit Hepatitis C Virus Replication

Dr Dmitry TSVELIKHOVSKY
Dr Dmitry TSVELIKHOVSKY
THE HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel
Read more

Rapid Composition of Tricyclic Spiranoid Lactones: Access to Natural Frames and Application in Selective Silencing of the Pain Receptor TRPV1

Dr Mario VAN DER STELT
Dr Mario VAN DER STELT
LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

Discovery of In Vivo Active and Selective Diacylglycerol Lipase-Alpha Inhibitors


With the support of

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Award & Prize Sponsors

Premium Exhibitors

Media Partners

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys